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Receptors for the Fc region of IgE (FcER)' have been found on a variety of
cell types of hemopoietic origin . High-affinity receptors are expressed on mast
cells and basophils, whereas low-affinity receptors (FccR,,) are expressed on T
and B lymphocytes, monocytes, and platelets (1-4) . FcER,-bearing lymphocytes
play a major role in the regulation of IgE production (5-7) . Recently, we reported
the generation of a hybridoma secreting mAb 25, which specifically recognizes
the 42,000 Mr FccR, expressed on human EBV-transformed B cell lines and on
a fraction of normal human B cells (8) . We and others (9) have demonstrated
that the CD23 antigen is an FccR,, since the CD23 mAbs inhibited the binding
ofIgE.
After fusion of splenocytes from mice immunized with either RPMI 8866 cells
or an enriched FCeR,,/CD23 preparation obtained from RPMI 8866 cells, we
obtained two mAbs, mAb 135 and 449114, respectively, which inhibited the
binding of IgE to FcER,,/CD23-bearing cells . Interestingly, these antibodies were
found to bind to cell lines that do not express the FccR,./CD23 . In this report, it
is shown that mAb 135 and 449114 bind to HLA-DR antigens and that the
FccR,,/CD23 is spatially associated with the HLA-DR antigens on the B cell
surface .
Production ofmAbs
Materials and Methods
mAb 135.
￿
BALB/c mice (Iffa Credo, Les Oncins, France) were injected intraperito-
neally three times with 5 X 10 7 RPMI 8866 cells in PBS at 4-wk intervals . 2 d before the
fusion, mouse serum samples were collected and were demonstrated to have anti-FcCR L
activity . The binding of IgE to RPMI 8866 cells was inhibited at 1/50,000 mouse antisera
dilutions using the assay described below .
Mouse spleen cells were fused with NS-1 myeloma cells (ratio 5:1) using polyethylene
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￿
DSF, dithio-bis-(succinimidyl propionate) ; FoER, receptors for
the Fc region of IgE ; FccR,, low-affinity receptors for the Fc region of IgE .
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glycol 1000 (Merck-Schuchardt, Darmstadt, Federal Republic of Germany). After incu-
bation overnight at 37°C in a 50-ml flask in complete RPMI 1640 medium as described
below, the cell suspension was distributed in 24-well plates in medium containing hypo-
xanthine-azaserine. 1 wk later, hybridoma supernatants were screened for their ability to
inhibit binding of IgE to RPMI 8866 cells. Hybridomasthat producedantibodies inhibiting
the binding of IgE were cloned and subcloned by limiting dilution.
mAb 449 B4.
￿
mAb 449 B4 was obtained from a mouse immunized with an enriched
preparation of FcER,,/CD23 derived from RPMI 8866 cells. Briefly, RPMI 8866 cells
were solubilized in extraction buffer (see below) containing 0 .5% NP-40. The cell extract
was passed on an IgE-Sepharose immunoabsorbent. The bound fraction was eluted with
glycine-HCI buffer, pH 3.0. BALB/c mice were repeatedly immunized by intraperitoneal
injections of the fraction included in CFA, and their spleen cells were fused with SP2/O-
Ag14 cells (10).
For ascites production, BALB/c mice were injected intraperitoneally with 0.5 ml of
pristane (Aldrich Chemical Co., Strasbourg, France). 10 d later, 107 hybridoma cells were
injected intraperitoneally and ascitic fluid was collected 2-3 wk later. The ascitic fluid
was centrifuged at 30,000 g for 30 min at 4 °C to remove lipids and cellular debris.
mAbs were isolated from ascitic fluid by affinity chromatography on protein A columns
according to manufacturers instructions (Bio-Rad Laboratories, Richmond, CA). In some
cases, mAbs were purified from culture supernatants by affinity chromatography on rabbit
anti-mouse Ig coupled to Affigel 10 (Bio-Rad Laboratories). The mAbs were eluted with
0.2 M glycine-HCI buffer, pH 2.5, and the pH was further adjusted to 7 .2 with 1 M
phosphate buffer. The isotype of the mAb was determined by Ouchterlony analysis using
polyclonal antibodies specific for mouse Ig classes and subclasses (Zymed Laboratories,
San Francisco, CA). Preparation of mAb F(ab')z and Fab' fragments, and biotinylation of
mAbs were performed according to standard procedures as described previously (8).
Cell Lines
The Burkitt lymphoma lines (Daudi and BJAB) were obtained from the American Type
Culture Collection (ATCC, Rockville, MD). These cell lines were cultured in RPMI 1640
(Flow Laboratories, Irvine, Scotland) supplemented with 10% heat-inactivated FCS, 100
U/ml penicillin, 100 tig/ml streptomycin, and 2 mM glutamine; all were purchased from
Flow Laboratories.
Monoclonal Antibodies
The mAb 25 is specific for the FcfR,, on B lymphocytes (8) and precipitates a 42,000
M,. polypeptide from EBV-transformed lymphoblastoid cell lines. The mAbs L243 (anti-
HLA-DR) (11) and B7/21 (anti-HLA-DP) were obtained from Becton Dickinson & Co.
(Mountain View, CA). The mAb IOT2 (anti-HLA-ABC) was obtained from Immunotech
(Luminy, France). The SPV-L3 mAb (anti-HLA-DQ) has been described previously (12).
The mAb I F5 (CD20) was a kind gift of Dr. E. Clark (University of Washington, Seattle,
WA).
Analysis with a FACS
Fluorescence analysis was performed with a FACS 440 (Becton Dickinson & Co.,
Sunnyvale, CA) equipped with a 5 W argon laser running at 488 nm, 0.5 W. Fluorescence
parameters were collected using a built-in logarithmic amplifier after gating on the
combination of forward light scatter (FLS) and perpendicular light scatter (PLS), which
was used to discriminate viable from nonviable cells.
Inhibition of the Binding of IgE to RPMI 8866 Cells.
￿
Hybridoma supernatants were
screened for their ability to inhibit the binding of IgE to RPMI 8866 cells as described
previously (13) or to inhibit rosette formation of RPMI 8866 cells with IgE-coated
erythrocytes (10). Briefly, 5 x 105 cells were incubated 30 min at 4'C under gentle
agitation with hybridoma supernatants (100 ul), in a 0 .2-ml microtiter plate well. After
two washes (150 g, 7 min) with PBS, 1 % BSA, 0 .1 % NaN3, soluble monomeric (IgE PS)
was added at a concentration of 10 ug/ml . The plate was then incubated 30 min at 4°C.BONNEFOY ET AL .
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Subsequently, cells were washed and incubated with a specific rabbit anti-human IgE
antiserum (1/1,000 diluted) for 30 min at 4 °C . Cells were then washed and incubated
with goat anti-rabbit Ig coupled to fluorescent microspheres (F1uoresbrite Carboxylate,
diameter 0.57 Am, ref. 15700 ; Polysciences, Inc ., Warrington, PA) for 30 min at 4°C .
Finally, the cell suspension was layered on 3 ml heat-inactivated FCS and centrifuged 15
min at 100 g to remove nonbound beads . The samples were resuspended in 200 A1 PBS,
BSA, NaN,, and analyzed by flow cytometry as described above . Under these conditions,
45-70% of the cells were fluorescent . mAb 25 (anti FctR,/CD23) stains a higher percent-
age of cells (80-95%) because it has a 1,000-fold higher affinity for the FcER,,/CD23 than
the IgE .
Single-Color Indirect Staining. Single- and double-fluorescence stainings were per-
formed in microtiter plates . 5 X 10 cells (in 50 Al) were incubated with 100 AI of
hybridoma supernatant or 10 A1 of mAb appropriately diluted . After two washes, cells
were incubated with fluoresceinated F(ab') 2 fragments of goat anti-mouse Ig (Grub,
Vienna, Austria) for 30 min at 4°C at a dilution of 1/100 . The stained cells were analyzed
with the FACS .
Two-Color Immunofluorescence. For double-fluorescence analysis, mononuclear cells
were incubated simultaneously with commercially available FITC-conjugated mAbs ap-
propriately diluted and biotinylated mAb 135 . The binding of biotinylated antibody was
assessed using phycoerythrin-conjugated streptavidin (Becton Dickinson & Co) .
Inhibition of the Binding ofmAbs.
￿
Inhibition of binding was carried out as follows. The
cell suspension was incubated with an excess of the first mAb for 30 min at 4°C . After
three washes with PBS/BSA, cells were incubated with a second biotinylated mAb (see
below) . After three washes, the binding ofthe second antibody was revealed by incubation
of the cells with phycoerythrin-conjugated streptavidin . After three washes, cells were
analyzed with the FACS .
Human B Lymphocyte Cultures with Human IL-4
B cells were isolated from tonsils obtained from children with chronic tonsillitis .
Mononuclear cells were separated on Ficoll/Hypaque . T cells were removed from the
mononuclear cells by twice rosetting with 2-aminoethylisothiouronium bromide (AFT,
Sigma Chemical Co ., St . Louis, MO)-treated sheep erythrocytes . Monocytes were depleted
by adhering 250 X 106 T cell-depleted cells to plastic flasks (Corning Glass Works,
Corning, NY) containing 25 ml RPMI 1640 with 10% FCS for 1 h at 37°C . The tonsillar
B cell preparations contained : >95% sIg+ cells, as determined by staining with a fluores-
cein-conjugated F(ab')2 fragment of goat anti-human Ig (Behring werke, Marburg,
Federal Republic of Germany) ; >95% CD20 antigen-positive cells, as determined by
staining cells with a mouse anti-human B cell-specific mAb antibody, B1 (Coulter
Immunology, Hialeah, FL) and fluorescenn-conjugated F(ab') 2 goat anti-mouse Ig (Grub) ;
<1% T cells, as determined by the Leu-1 mAb (Becton Dickinson & Co.) ; <1% monocytes,
as determined by the Leu-M3 mAb (Becton Dickinson & Co) .
For activation, the purified B cells were cultured at a density of 106 cells/ml in Iscove's
medium enriched with 50 Ag/ml human transferrin, 0.5% BSA, and oleic, linoleic, and
palmitic acid (all from Sigma Chemical Co.) as described by Yssel et al . (14) . 2% of FCS
was added to the medium . Rabbit anti-IgM antibody coupled to beads (Bio-Rad Labora-
tories) was added at a final concentration of 5 wg/ml . Human rIL-4 (15) was added as a
COS-7 transfection supernatant at a final concentration of 1% (80 U/ml). 1 U of IL-4 is
defined as the amount resulting in a half maximal [sH]TdR uptake in activated PHA
blasts (15) .
This lymphokine is able to induce FctR,/CD23 on normal human B lymphocytes (16,
17) . After 48 h of culture, viable B lymphocytes were separated from the nonviable cells
by centrifugation on a Ficoll/Hypaque gradient and were surface labeled as described
below .
Cytotoxicity Inhibition Assay
The cytotoxicity inhibition assay was carried out as described elsewhere (18) . Briefly,
5'Cr-labeledJY cells were incubated with diluted samples of different mAbs . Then effector60
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cells were added and after 4 h of incubation, supernatants were harvested, counted, and
lysis was calculated with the formula: Percent specific lysis = 100 x [(cpm of sample) -
(cpm of medium control)]/[(cpm in presence of Triton x 100) - (cpm of medium
control)].
The alloreactive cytotoxic IL-2-dependent human T cell clones HY640 and JR-2-10
(19) were used as effector cells. The clones HY640 and JR-2-10 specifically recognized
HLA-DQ-1 and HLA-DRW6 antigens, respectively, on JY cells.
Immunoprecipitation and SDS-PAGE,
5 x 10' RPMI 8866 cells or rIL 4-treated B lymphocytes were washed twice with PBS
containing 1 mM PMSF (Sigma Chemical Co.) and then resuspended in 1 ml PBS/0.5
mCi '251-Na (Oris, Saclay, France); 100 Al lactoperoxidase at 5 mg/ml (Calbiochem-
Behring Corp., La Jolla, CA), and 50 IAI H202 (0.03% in water) were added. After 3 min
of gentle agitation at room temperature, another 100 jl of lactoperoxidase and 50 Al of
H202 were added. The suspension was again agitated for 3 min at room temperature.
This step was repeated once again and the cells were finally washed with PBS containing
5mMK1.
Cells were resuspended at 0°C for 15 min in 300 jul extraction buffer composed of
PBS, pH 7.8, with the protease inhibitors: 20 mM iodoacetamide, 1 mM PMSF, 0 .01 M
benzamidine hydrochloride, 1 wg/ml each of leupeptin, pepstatin, and 100 Ag/ml soybean
trypsin inhibitor (all from Sigma Chemical Co.) containing either 0.5% NP-40 or 1%
digitonin (Aldrich Chemical Co.). Digitonin was prepared as a 2% stock solution: the solid
detergent was added to boiling water, which was stirred for 2 min, cooled, allowed to
stand at room temperature for 1 wk, and then filtered. The lysates were then centrifuged
at 10,000 g for 15 min and the supernatant at 100,000 g for 30 min before preclearing
overnight with a 50-jl packed volume of protein A-Sepharose beads (Pharmacia Fine
Chemicals, Uppsala, Sweden) precoated with a nonrelated mAb (100 Al of ascites).
Immunoprecipitation was performed by incubating the extract for 4 h at room tempera-
ture with 50 ,tcl protein A-Sepharose beads precoated with the different mAbs . Immu-
noprecipitates were washed five times with the extraction buffer and subjected to SDS-
PAGE using the method of Laemmli (20). The gels were then fixed, dried, and autora-
diographed using X-GMAT AR-05 film (Eastman Kodak, Paris, France) at -70°C.
Protein Elutionfrom SDS-PAGE Gel
The SDS-PAGE gel containing the 42,000 M,- polypeptide isolated by Immunoprecipi-
tation with mAb 135 from 115I-labeled and dithio-bis-(succinimidylpropionate) (DSP)-
crosslinked RPMI 8866 cell lysates, was sliced into small pieces and a carrier protein,
BSA, (Sigma Chemical Co.) was added. The polypeptide was eluted in extraction buffer
mentioned above for 20 h at 37 ° C. After centrifugation, 12,000 rpm for 30 min, the
supernatant was then immunoprecipitated with mAb 25 or with normal mouse Ig as
control.
Crosslinking
Radiolabeled cells were resuspended at 3.10'/ml in PBS pH 7-4 containing 1 mM
MgCl2, 0.02% sodium azide. The cleavable crosslinker DSP (Pierce Chemical Co., Rock-
ford, IL) was dissolved in DMSO at a concentration of 10 mM and added to the cell
suspension at a final concentration of 1 mM. Reaction was allowed to occur for 30 min at
4°C under gentle agitation. After two washes with PBS to remove free DSP, the cell
suspension was lysed and immunoprecipitations were carried out as described above.
Results
Certain mAbs Speeifcfor HLA-DR Antigens Partially Inhibit the Binding of
IgE to FCERL/CD23
To obtain mAbs specific for the FcER,, the supernatants of hybridomas
obtained from a mouse immunized with the FcER, + RPMI 8866 cell line wereBONNEFOY ET AL .
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FIGURE 1 .
￿
mAb 135 inhibits
the binding of IgE to RPMI
8866 cells . (A) RPMI 8866
cells were incubated with 10
,ug/ml of IgE (open) or without
IgE as negative control
(shaded), then with polyclonal
anti-IgE antiserum and goat
anti-rabbit Ig coupled to flu-
orescent microspheres . (B)
RPMI 8866 cells were prein-
cubated with 50 ug/ml ofmAb
135 (shaded) or without (open)
then reacted subsequently
with IgE, polyclonal anti-IgE antiserum andgoat anti-rabbit Ig coupled to fluorescent microspheres .
(C) RPMI 8866 cells were preincubated with 50 Mg/ml of mAb IOT2 (anti HLA-ABC) (shaded) or
without (open), then treated as in A and B. Fluorescence was analyzed by flow cytometry . Abscissa,
log fluorescence intensity ; ordinate, relative number of cells .
screened for their ability to inhibit the binding of IgE to the same cells . The
supernatant of one hybridoma, 9P135, inhibited the binding of IgE as deter-
mined in an indirect fluorescent microspheres assay . One subclone of this
hybridoma was selected that secreted mAb 135 (IgG1) (Fig . 1). Purified mAb
135 and its derived F(ab')2 and Fab' fragments inhibited the binding of IgE to
RPMI 8866 cells (Table I), and several other EBV-transformed cell lines (data
not shown), in a dose-dependent manner . In contrast with mAb 25 (anti-
FC(R,/CD23), which totally inhibits the binding ofIgE to its receptor, mAb 135,
even at high concentrations, only partially inhibits IgE binding to the FCeR,
MAb 135 decreases both the percentage of cells binding IgE and the fluorescence
intensity of cells that still bind IgE (Fig. 1) . RPMI 8866-reactive nonrelated
mAbs such as mAb IOT2 (anti-HLA-ABC) and the CD20 mAbs 1F5 and 111
failed to inhibit IgE binding to RPMI 8866 cells (Table 1, and data not shown) .
mAb 135 was, however, found to bind to FcER,,/CD23- cells (e.g ., Daudi, BJAB).
Immunoprecipitation analysis demonstrated that mAb 135 precipitated two
polypeptides of 36,000 and 28,000M r (Fig . 2), suggesting that it was specific for
the HLA class II antigens . Binding of mAb 135 analyzed by flow cytometry to a
largepanel of cell lines differentially expressingHLA-DP, -DQ, and-DR antigens
suggested that it was binding to HLA-DR antigens (not shown here) . The
specificity ofmAb 135 for HLA-DR antigens was further substantiated by the
finding that mAb 135 was able to specifically inhibit the cytotoxicity of the T
cell cloneJR-2-10 recognizing HLA-DR antigens on theJY target cells, whereas
the cytotoxicity of the T cell clone HY640 recognizing HLA-DQ antigens was
not affected by mAb 135 (Table II) . Another mAb, 449114, obtained from a
mouse immunized with enriched FcER,/CD23 preparations, was found to inhibit
the binding of soluble IgE to EBV cell lines and inhibit rosette formation of
RPMI 8866 cells with IgE-coated ox erythrocytes . Furthermore, mAb 449114
was found to inhibit the binding ofmAb 135 to a variety ofcell lines (not shown)
and to precipitate two polypeptides with 36,000 and 28,000Mr , demonstrating
that it had the same specificity as mAb 135 . The sequence of the 36,000 M,
polypeptide recognized by mAb 449114 proved to be identical to the sequence
of HLA-DRa, and the sequence of the 28,000 M, polypeptide, also identified by62
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TABLE I
mAb 135 Inhibits IgE Binding to its Receptor on RPM18866 Cells
via its Fab Fragments
* Cellswere incubatedwith intact mAb 135, F(ab')2, Fab' or Fc fragments
andnonrelated mAb(ascontrol). Then 10 jig/ml ofIgE, polyclonal anti
IgE antiserum and goat antirabbit Ig coupled to microspheres were
successively added.
r Calculated accordingto the formula: Percentinhibition = 100 x ((assay
- C-)/(C' - C-)] (normalized values of 3 assays).
§mAb25 was used at 10 ug/mland stained 90% of cells.
mAb IOT2 (anti HLA ABC) was used at 50,ug/ml and stained 98% of
cells.
IgE was omitted in the microsphere assay procedure.
mAb 449B4, was shown to be homologous to reported sequences of HLA-DRO
(Dr. M. Bond, DNAX Research Institute, personal communication). This dem-
onstrated that certain anti-HLA-DR antibodies are able to partially block the
binding of IgE to FcERL/CD23, suggesting a possible association of HLA-DR
antigens with FccRL/CD23. Not all the anti-HLA-DR antibodies were found to
inhibit the binding of IgE. The well-characterized mAb L243 (11) was unable to
inhibit the binding of IgE to FcERL/CD23+ cell lines and was also unable to
inhibit the binding of mAb 135 (Fig. 3) to the same cell lines, demonstrating
that these antibodies are binding to different epitopes of the HLA-DR molecule.
An mAb specific for HLA-DQ antigens (12) and an mAb specific for HLA-DP
antigens were unable to inhibit the binding of IgE to RPMI 8866 cells.
Anti-HLA-DR antigen mAbs may therefore be divided into two well-defined
groups: one group inhibiting the binding of both IgE and mAb 135 and a second
group that does not affect the binding of IgE or mAb 135. Nevertheless, both
groups of antibodies bound 36,000 and 28,000 Aproteins expressed on the cell
mAb FcER,' cells* Inhibition IgE
binding
mAb 135
50 jAg/ml 26 44
20,ug/ml 34.6 22
10 jug/ml 39.6 9
F(ab')2 mAb 135
50,ug/ml 29 36
20 jug/ml 36.5 17
Fab' mAb 135
50 gg/ml 34 24
20,ug/ml 37.7 14
Fc mAb 135 48 0
mAb 25§ 8.1 91
Nonrelated mAb: C'1 43.1 0
C-' 4.5C:TL
clone
TABLE II
The Effect ofAntibodies against Class II MHCAntigens on the Lysis offY Cells by
Two CTL Clones
fR-2-10
HY-640
BONNEFOY ET AL .
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FIGURE 2.
￿
Immunoprecipitation of surface proteins of radiolabeled
RPMI 8866 cells . RPMI 8866 cells were labeled by surface iodination
(Na-1251) with lactoperoxidase and solubilized with NP-40 lysis buffer .
After preclearing, cell extracts were incubated with mAb 25 (A), mAb
135 (B), and normal mouse Ig (NMIg) (C) . After SDS-PAGE, labeled
immunoprecipitated proteins were revealed by .autoradiography . Pre-
stained molecular weight standards were coelectrophoresed phospho-
rylase B (97,000), BSA (68,000),OVA (43,000), and a-chymotrypsin-
ogen (26,000) .
"Cr-labeledJY cells were incubated with different mAbs and used as targets in a cytotoxicity assay with class 11 MHC antigen-
specific CTI, clone.
* Cytotoxicity was measured atan E/T ratio of 5:1 .
* Reciprocal dilution of ascites fluid .
surface . Immunoprecipitation experiments excluded the possibility that the anti-
HLA-DR mAbs inhibiting the binding of IgE were recognizing an epitope
common to both HLA-DR and FCERL/CD23, since the latter molecule could not
be immunoprecipitated by these antibodies .
Taken together, these data demonstrate that certain mAbs directed against
HLA-DR antigens have the ability to inhibit partially the binding of IgE to
FceRL/CD23 and suggest a physical interaction between FcERL/CD23 and HLA
DR antigens .
Spatial Association between FccR,,/CD23 andHLA-DR Antigens
Crosslinking Studies.
￿
One approach to studying the possible physical associa-
Lysis of
the con-
trol
SPV-L3 (anti-
HLA-DQ)
Percent lysis
449114 (anti-
HLA-DR)
in the
L243
presence
(anti-
HLA-DR)
ofantibody*
mAb
HLA-DR)
135 (anti- mAb
(anti-FceRL)
25
100* 500 100 500 100 500 100 500 100 500
%
39 3 3 40 32 41 39 47 36 39 37
50 49 46 6 18 5 20 5 13 46 4664
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FIGURE 3 .
￿
Staining of RPMI 8866 cells with the mAbs L243 and mAb 135 . RPMI 8866
cells were stained with normal mouse Ig (NMlg) and goat anti-mouse coupled to FITC (A),
with biotinylated mAb 135, revealed with phycoerythrin-streptavidin (B), with FITC conju-
gated L243 (C), or cells were double-stained with biotinylated mAb 135 and FITC-conjugated
L243 . Biotinylated mAb 135was developed with phycoerythrin-streptavidin (D). Samples were
analyzed with a FACS 440 with logarithmic amplification .
tion of two cell surface molecules on the cell membrane surface is chemical
crosslinking . This approach was used to show the association between the T cell
receptor and the CD3 complex (21) and the association between the insulin
receptor and the HLA class I antigens (22) . To study the possible physical
association between FcERL/CD23 andHLA-DR antigens, 125I-labeledRPMI 8866
cells were crosslinked with DSPand the NP-40 cell lysate was then precipitated
with either mAb 135 or mAb 25 (anti-FcER L/CD23) . SDS-gel analysis shows that
mAb 135 precipitated, in addition to the expected 36,000 and 28,000Mr class
II MHC polypeptides, a 42,000 Mr polypeptide and, weakly, a 90,000 smear
(Fig . 4) . The anti-HLA-DR mAb L243 also precipitated these three major
polypeptides from the crosslinked cell extract (not shown) . To demonstrate that
the 42,000 M, polypeptide was the FcER,/CD23, the SDS-PAGE gel was sliced
in the 40,000-45,000 M, area and the protein was eluted and subjected toBONNEFOY ET AL.
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FIGURE 4. FcfR L/CD23 and HLA-DR anti-
gens are spatially associated on RPMI 8866
cells . RPMI 8866 cells were labeled by surface
iodination with 1251-lactoperoxidase and solu-
bilized with digitonin lysis buffer or treated
with DSP andthen solubilized with NP-40 lysis
buffer . After preclearing, the cell lysates were
immunoprecipitated with mAb 25 (A), mAb
135 (B), or normal mouse Ig (C). The precipi-
tates were analyzed in the same conditions as
in Fig. 2 . Arrows indicate the migration of
FctR,, andHLA-DR antigens .
precipitation with the FcER,/CD23-specificmAb 25 . Fig. 5 shows that the eluted
polypeptide could specifically be precipitated by mAb 25, thus demonstrating
that the 42,000Mr polypeptide coprecipitated with the anti-HLA-DR antibody
mAb 135 was indeed FcfRL/CD23 . The smear around 90,000 Mr was also
present and most probably represents an aggregated form of the FCER,,/CD23.
Conversely, mAb 25 precipitated in addition to the expected 42,000 M,
FcER,,/CD23 polypeptide and 90,000 M, smear, two polypeptides with 36,000
and 28,000 M, when cell surface components on RPMI 8866 cells were cross-
linked (Fig . 4) .
Digitonin Cell Extract .
￿
The use of the detergent digitonin made it possible to
prepare cell extracts in which complex receptors composed of noncovalently
linked proteins could be isolated (23) . Therefore 1251-labeled RPMI 8866 cells
extractswere prepared using digitonin and immunoprecipitated with either mAb
25 or mAb 135. Under these conditions, mAb 25 was able to precipitate, in
addition to the expected 42,000M r FcER,/CD23, the polypeptides with 36,000
and 28,000 M, (Fig . 4) . Conversely, mAb 135 coprecipitated with the expected
36,000 and 28,000M, polypeptides, the 42,000M, molecule (Fig . 4) . The90,000
M r smear was also found under these conditions .
Taken together, these biochemical data demonstrate that the FcER L/CD23 and
HLA-DR antigens are spatially associated on the cell surface ofEBV-transformed
B cell lines .
The IL-4-induced FcER,ICD23 on NormalB Cells Is Associated with HLA-
DR Antigens
It has recently been shown that human IL-4 (B cell stimulatory factor I
[BSFI]) (15) was able to induce a strong expression of FcER,,/CD23 on normal B66
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FIGURE 5 .
￿
The 42,000 M, molecule precipitated with mAb 135
after DSP crosslinking of labeled RPMI 8866 cells is the
FcER,,/CD23 antigen . RPMI 8866 cells were cell surface iodinated .
After DSPtreatment, labeled cells were solubilized with NP-40 lysis
buffer. After preclearing, the cell lysateswere immunoprecipitated
with mAb 135 (A) . The 42,000-45,000 M, polypeptides isolated in
Awere eluted andimmunoprecipitated with mAb25 (B)andnormal
mouse Ig (NMIg) as control (C) .
lymphocytes (16, 17). We therefore investigated whether the IL-4-induced
FcER,./CD23 on normal B lymphocytes was spatially associated with HLA-DR
antigens as demonstrated above on the EBV-transformed cell lines . Purified
tonsil B cells were cultured for 48 h with rIL-4 (80 U/ml) in the presence of
anti-IgM antibody coupled to beads, conditions that were found to be optimal
for the induction of FcER,,/CD23 . As a control, cells were cultured with anti-
IgM antibody coupled to beads, which does not induce a significant expression
ofFcER,,/CD23 . Viable cells, obtained after centrifugation over Ficoll/Hypaque,
were labeled with 121-lactoperoxidase and crosslinked with DSP. The NP-40
extract was precipitated with mAb 135 or mAb 25 . In Fig . 6 it is demonstrated
that mAb 135 is able to precipitate the three bands with 42,000, 36,000, and
28,000 Mr from the rIL-4-cultured B cells . Conversely, mAb 25 coprecipitated
with the expected 42,000Mr FCER,/CD23, the 36,000 and 28,000M r polypep-
tides from the rIL-4-cultured B cells . The 90,000M r smear was also observed in
the IL-4-treated cells . From control cells, which are FcER,/CD23- negative and
DR', mAb 135 could only precipitate the 36,000 and 28,000M r polypeptides,
and mAb 25, as expected, no polypeptide . These results demonstrate that the
IL-4-induced FcER,/CD23 on normal B cells is spatially associated with HLA-
DR antigens .BONNEFOY ET AL.
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Discussion
FIGURE 6 .
￿
The IL-4-induced FccR L/CD23on
normal humanB cells is spatially associated with
HLA-DR antigens . IL-4-induced (+) or nonin-
duced (-) purified human B cells were cell
surface iodinated . After DSP treatment, la-
beled cells were solubilized with NP-40 lysis
buffer . After preclearing, the cell lysates were
immunoprecipitated with mAb 135 (left) or
with mAb 25 (right) . The precipitates were
analyzed as described in Fig. 2 . Arrows indicate
the position of FceR~ and HLA-DR antigens .
We have previously described the generation of mAb 25, which specifically
recognized the FccR,,/CD23 (8), and blocked the binding of IgE to human B
cells . We found two other mAbs (mAbs 135 and 449 B4) that partially inhibited
the binding of IgE to the low-affinity receptor for IgE on the EBV-transformed
lymphoblastoid cell line RPMI 8866 . These antibodies decreased both the
percentage of cells binding IgE and the fluorescence intensity of cells that still
bind IgE. mAb 135 was obtained from fused splenocytes ofa mouse immunized
with RPMI 8866 cells, whereas 449 B4 was obtained from fused splenocytes of
a mouse immunized with an enriched preparation of FceR,, derived from RPMI
8866 cells .
Unlike mAb 25, mAbs 135 and 449 B4 were able to stain FcER,,/CD23- cell
lines (Daudi, BJAB). This suggested that these antibodies were binding to either
an epitope common to FcER,,/CD23 and to another cell surface molecule or to
an antigen not antigenically related to the FcER,,/CD23 but linked to it in such a
fashion that the binding of the mAb 135 or mAb 449 B4 would affect the
binding ofIgE to the FccR,/CD23 .
The partial inhibition of binding of IgE by mAbs 135 and 449B4 and the
finding that some Fc(R,,/CD23 could still be immunoprecipitated by mAb 25
from NP-40 extracts of DSP crosslinked cells precleared with mAb 135 (data
not shown) suggest that not all the Fc(R,,/CD23 were associated with the HLA-
DR antigens . Immunofluorescence analysis performed with a panel of cell lines
differentially expressing HLA-DR antigens (as well as DP and DQ, not shown
here), biochemical analysis (immunoprecipitation of 36,000 and 28,000 Mr68
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polypeptides), inhibition of cytotoxicity of HLA-DR-specific T cell clones, and
protein sequencing of mAb 449114-recognized antigen (Dr. M. Bond, DNAX
Research Institute, personal communication) demonstrated that mAb 135 and
449114 were specific for HLA-DR antigens. This suggested that the FcERL/CD23
was somehow associated with HLA-DR antigens. It could be excluded that the
mAb 135 and 449114 were binding to an epitope common to FcERL/CD23 and
HLA-DR since they only precipitated the HLA-DR polypeptides under standard
conditions. Interestingly, not all the anti-HLA-DR mAbs were able to inhibit the
binding of IgE. For instance, the well-characterized anti-HLA-DR mAb L243
(11) was unable to inhibit the binding of either IgE or mAb 135 to RPMI 8866
cells, suggesting that mAb L243 binds to an epitope of the HLA-DR molecule
distant from the site of interaction of HLA-DR molecules with the FceRL/CD23.
To study the possible association of HLA-DR antigens and FceRL/CD23,
125I-
Na-lactoperoxidase-labeled cells were crosslinked with DSP and solubilized with
NP-40. The anti-FceRL/CD23 mAb 25 could precipitate the expected 42,000 M,
polypeptide, a 90,000 M, smear, and two polypeptides of 36,000 and 28,000 M,.
Conversely, mAb 135 and 449 B4 precipitated the 42,000 M, polypeptide and
the 90,000 M, smear, in addition to the expected 36,000 M, and 28,000 M,
polypeptides. The 42,000 M, polypeptide precipitated by anti-HLA-DR antibod-
ies was found to be the FceRL/CD23 since it could be precipitated by mAb 25
after solubilization from the SDS-PAGE gel. The smear around 90,000 M, has
been previously suggested to represent an aggregated dimer of the 42,000 M,
band (24). Moreover this 90,000 M, band, inconstantly found, appeared when
the 42,000 M, eluted material was stored at -20°C for a few days before use
(data not shown). When intact noncrosslinked labeled cells were solubilized with
Digitonin instead of NP-40, a procedure that maintains the noncovalent associ-
ation between the different polypeptides of complex receptors (23), mAb 25
could immunoprecipitate the 28,000 and 36,000 M, polypeptides together with
the 42,000 Mr polypeptide. Conversely, the mAb 135 was able to precipitate the
42,000 Mr polypeptide in addition to the 28,000 and 36,000 M, ones . This
suggests that the FceRL/CD23 is spatially associated with the HLA-DR antigens
on the B lymphocyte cell surface. Finally the association of FceRL/CD23 with
HLA DR antigens is further confirmed by the fact that the anti-HLA-DR mAb
449 B4 was obtained after immunizing mice with the partially purified FcER,,/
CD23 eluted from an IgE immunoabsorbent. The demonstration of a physical
association between FcER,,/CD23 and HLA-DR antigens on the surface of cell
lines raises the question as to whether this phenomenon is linked to the transfor-
mation induced by EBV. This is particularly relevant since only a fraction of
normal B cells express at very low levels the FcER,./CD23 . Recently, it has been
demonstrated that human IL-4 (15) is able to induce the FcER,,/CD23 on normal
Bcells (16, 17). We thereforeinvestigated whetherthe IL-4-induced FceRL/CD23
antigen was associated to HLA-DR antigens. Crosslinking experiments demon-
strated that the IL-4-induced FceRL/CD23 on normal B cells is also associated
with HLA-DR antigens. This demonstrated that the association of FCER,,/CD23
with HLA-DR antigens is not a consequence of the transformation of B cells by
EBV.
Association between Fc receptors for IgG and MHC class 11 molecules on BBONNEFOY ET AL.
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lymphocytes has been reported earlier in rodents, since anti-la antibodies inhib-
ited the binding of IgG complexes (25-28). It was further proposed that this
inhibition was indeed due to an alteration of the la antigens mediated by the
binding of the anti-la antibody and resulting in the association of the la antigens
with the Fc receptors, independent of the anti-la antibody Fc fragment (29).
Thus, although these observations showing interaction of murine MHC class 11
antigen with FcyR correlate with our observation that human MHC class II
antigens are associated with FCER,, conclusions ofthese studies differ. It therefore
seems of interest to reinvestigate the possible physical association of murine
MHC class II antigens with FcyR using the biochemical approach described in
our study. Actually, soluble IgG binding factors derived from mouse T cells
were found to be absorbed by anti-la antisera (30, 31), suggesting either a
physical association between IgG binding factors and la antigens or the presence
of common antigenic determinants on both structures. Actually, the presence of
antigenic determinants common to rodent MHC class II antigens and IgE binding
factors was recently reported since OX3 mAb was able to recognize an epitope
containing an N-linked oligosaccharide common to la antigens and 60,000 Mr T
cell-derived IgE suppressive factors (32, 33).
Association between other cell surface receptors and HLA antigens has been
reported recently. First, an anti-HLA class I mAb was found to effectively inhibit
the binding of insulin to insulin receptors (34). Upon crosslinking of cell surface
antigens the insulin receptor has been shown to coprecipitate with HLA class I
antigens (22, 34, 35). Second, a monoclonal as well as a polyclonal anti-HLA
class I antibody have been found to inhibit the binding of epidermal growth
factor (EGF) to A431 cells (36). This inhibition required crosslinking of HLA
antigens since Fab fragments needed to be crosslinked with an anti-mouse Ig
antibody to be effective . This suggests that the mechanisms of inhibition of EGF
binding by anti-HLA class I antibodies is different from the mechanisms of
inhibition of IgE binding by anti HLA-DR antibodies.
It remains to be determined whether the anti HLA-DR antibodies inhibiting
the binding of IgE are specific for the HLA-DR a or HLA-DR ,8 chain. Finally,
a further investigation of the possible biological function of the FcERL/CD23-
HLA-DR complex must await an understanding of the role of FcERL/CD23 itself.
Summary
Two hybridomas that produce the mAbs 135 and 449 B4 were obtained that
inhibited the binding of IgE to the FccR,/CD23 on the EBV-transformed B cell
line RPMI 8866. mAb 135 was obtained from a mouse immunized with RPMI
8866 cells, whereas mAb 449114 was obtained from a mouse immunized with a
partially purified preparation of FcER,/CD23 obtained as the eluate of an IgE
immunoabsorbent loaded with a soluble extract of RPMI 8866 cells. These two
mAbs bound to FcER,,/CD23- cell lines and precipitated two polypeptides with
36,000 M, and 28,000 M,, which were the HLA-DR a and a chains, respectively.
Immunoprecipitation with mAb 135 of NP-40 lysates from dithio-bis-(succi-
nimidyl propionate) (DSP) crosslinked 125I-labeled RPMI 8866 or normal B cells
incubated with rIL-4 showed three polypeptides with 42,000, 36,000, and 28,000
Mr. The 42,000 M,. polypeptide is identical to the FcER,,/CD23 since it could be70
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precipitated by the anti-FcER,/CD23 mAb 25 after resolubilization from the
SDS-PAGE gel . Immunoprecipitations of the crosslinked cell extracts carried out
with the anti-FcER,,/CD23 mAb 25 yielded the same three polypeptides. Fur-
thermore, when RPMI 8866 or rIL-4 preincubated normal B cells were solubi-
lized with a digitonin buffer, which prevents the dissociation of noncovalently
linked polypeptide complexes, mAb 135 and mAb 25 precipitated complexes
composed of three molecules with 42,000, 36,000, and 28,000 M,. The well-
characterized anti-HLA-DR mAb L243 was unable to block the binding of either
IgE or mAb 135 to RPMI 8866 cells, although it could immunoprecipitate the
complex (HLA-DR-FccRL/CD23) from crosslinked cell lysates . Since mAb 135
and L243 were able to both bind the RPMI 8866 cells, it demonstrates that they
bind to different epitopes of the HLA-DR complex, the mAb 135 epitope of the
HLA-DR molecule being close to the IgE binding site of the FcERL/CD23. These
data demonstrated that the FCER,/CD23 and HLA-DR antigens are spatially
associated on the B cell membrane.
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